Scarletred Arora AI - Setting a new standard in cancer irradiation therapy and dermatology care!
Medtech scale-up SCARLETRED achieves a major milestone: its AI-powered skin imaging solution “Arora” enters clinical routine at LKH University Hospital Graz, setting new standards in cancer therapy and dermatology care.
After more than a decade of groundbreaking innovation, Scarletred proudly announces a major clinical milestone. The AI-powered medical solution, “Arora” is now officially integrated into clinical routine use at the LKH University Hospital Graz in Austria, marking a new era in oncology and clinical care. This milestone has been realized in close collaboration with Dr. med. Richard Partl, Specialist in Radiation Oncology and Clinical R&D. The AI is used to automatically detect and measure skin reactions in patients during radiation therapy. According to Dr. med. Richard Partl:
Artificial intelligence is now being applied in various areas of radiation oncology. With the AI agent ‘Arora’, we can, for the first time, record radiation-induced skin reactions efficiently and precisely - like a Swiss watch. This improves the quality of treatment. Moreover, this digital tool eases the workload of doctors in their daily clinical routines and places patients even more at the center of care.
Since incorporation in 2014, the company Scarletred has evolved from a visionary startup into a global leader in AI-driven digital dermatology. The certified medical device platform Scarletred®Vision seamlessly combines advanced image analysis with artificial intelligence to objectively monitor and quantify skin conditions - delivering clinical-grade precision at scale. The powerful AI engine “Arora” is capable of analyzing complex skin data in milliseconds and covering over 3,000 dermatological conditions. This breakthrough sets new standards in precision medicine, accelerating drug development, reducing clinical risks, and lowering research costs.
The clinical rollout of “Arora” in clinical routine represents a defining moment - not just for our company, but for the entire field of AI-enhanced healthcare. Headquartered at the Vienna BioCenter, Scarletred continues its global expansion - from Europe to Boston and Japan - as its technology shapes the future of AI-driven dermatology and oncology.
Like the article? Spread the word
